WASHINGTON, D.C. (November 13, 2019)––The Council for Quality Respiratory Care (CQRC)—a coalition of the nation's leading home oxygen therapy provider and manufacturing companies—commends a bipartisan bill recently introduced in the House of Representatives that will help ensure America’s most vulnerable respiratory patients receive uninterrupted access to the non-invasive ventilators (NIV) they need to live.

Research in noninvasive ventilation for COPD treatment.

NEW YORK (February 12, 2018)—Jeremy Orr, MD, of University of California, San Diego, has been awarded the new ATS Foundation/ResMed Research Fellowship in Noninvasive Ventilation (NIV) in COPD.

ResMed is a provider of NIV devices for treating COPD (chronic obstructive pulmonary disease) in the home and hospital.

Dr. Orr’s $100,000 award will support his research focused on the impact of noninvasive ventilation on cardiovascular biomarkers in COPD.

Philips study shows 92 percent of patients are not receiving PAP therapy.

TUCSON, Ariz. (July 10, 2017)—COPD hospitalizations are at an all-time high. The 30-day readmission rate for patients ranges from 20 to 39 percent, with related health care costs at an estimated $50 billion. A recently published study, funded by Royal Philips, revealed that although positive airway pressure (PAP) therapy was associated with a reduction in hospitalization, more than 92 percent of patients studied were not receiving it in any form.

AMSTERDAM (June 16, 2016)—Philips Respironics, a business of Royal Philips, introduced the Wisp Pediatric Nasal Mask, which supports non-invasive ventilation (NIV) and is the most recent addition to the Wisp family of masks. Designed specifically for children, the Wisp Pediatric Nasal Mask features a child-friendly giraffe fabric pattern, a modified cushion curvature and support tools to help provide a positive experience for young patients and their families.